Mandate

Vinge has advised Sveafastigheter in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Sveafastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 13 June 2025 and the trading on Nasdaq Stockholm commenced on 18 June 2025.

Sveafastigheter is a real estate company that owns, actively manages and develops residential properties throughout Sweden with a focus on rental apartments in selected growth regions. The property portfolio consists of standing assets, ongoing construction and project development with a total property value of approximately SEK 28.2 billion.

Vinge’s team has primarily consisted of Rikard Lindahl, Benjamin Vafaeian, Filip Magnusson and  Carl Lexenberg (Capital Markets and Public M&A), Victor Ericsson, Emelie Svanberg, Erik Kochbati and Marcus Svärd (Corporate Tax), Emil Lindwall and Agnes Pigg (Employment), Felix Möller and William Carlberg Johansson (Financing), Ian Jonson (IPR), Kristoffer Larson (Real Estate) and Diana Kanold (VDR).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026